Biotechnology · Intermediate

Applications of recombinant DNA technology

Written by SignalsLab

Early edition: these lessons are being reviewed.

Content

Summary

Recombinant DNA technology enables the creation of new strains by transferring, removing, or altering DNA sequences in microbes, plants, and animals. This revolution facilitates the production of therapeutic proteins, vaccines, and novel chemical compounds, as well as the alteration of phenotypic properties for agricultural and medical benefits.

Intuition

Think of recombinant DNA technology as a precise editing tool for life's source code, moving far beyond traditional selective breeding. By inserting, deleting, or modifying specific DNA sequences, scientists can program organisms like bacteria, yeast, or mammalian cells to act as tiny factories. For instance, while E. coli is cost-effective for simple proteins, it lacks the machinery for complex modifications like glycosylation; thus, mammalian cells are chosen when proper folding and sugar-chain addition are critical for the protein's function. This flexibility allows us to not only replicate human proteins like insulin but also engineer enhanced versions or entirely new metabolic pathways to produce plastics, vitamins, or pest-resistant crops.

Derivation

  1. Recombinant DNA technology involves transferring, removing, or altering DNA sequences in host organisms.
  2. This process creates new strains or varieties capable of specific tasks, such as producing therapeutic proteins.
  3. Host selection depends on protein complexity: E. coli is used for simpler proteins (accumulating as inclusion bodies), while mammalian cells are used for complex proteins requiring glycosylation and correct folding.
  4. Protein engineering further modifies these molecules (e.g., amino acid replacement) to improve efficacy, longevity, or combine functionalities like antibody binding with cytokine activity.

Worked example

Problem

A pharmaceutical company needs to produce a complex human anticoagulant that requires glycosylation for proper function. They are choosing between E. coli and CHO (Chinese Hamster Ovary) cells. Which host should they select and why?

  1. Identify the requirement: The protein requires glycosylation (addition of sugar chains) for function.
  2. Evaluate E. coli: E. coli produces aglycosylated proteins and accumulates them as inclusion bodies, requiring in vitro refolding.
  3. Evaluate CHO cells: Mammalian cells, such as CHO cells, can perform glycosylation in vivo and achieve correct folding.
  4. Conclusion: CHO cells are the appropriate choice because they provide the necessary post-translational modifications that E. coli cannot.

Answer CHO cells should be selected because they support in vivo glycosylation and correct folding, which are essential for the complex protein's function, whereas E. coli produces aglycosylated proteins.

Common mistakes

  • Assuming E. coli can perform glycosylation; it produces aglycosylated proteins that often require in vitro refolding.
  • Believing early recombinant proteins were modified; early commercial proteins were exact copies of human molecules, while modern approaches allow significant modification.
  • Ignoring the risk of early cadaveric human growth hormone, which limited supply and risked Creutzfeld–Jacob syndrome.

Animation

Animation coming soon

The animated version of this lesson is being prepared for the web. In the Signals AI app, lessons are drawn step by step.

Code

This is a text lesson: it has no animation code yet.

ccBYNC© 2026 SignalsLab. Lesson text shared as is under CC BY-NC 4.0.